Welcome to our dedicated page for Zevra Therapeutics news (Ticker: ZVRA), a resource for investors and traders seeking the latest updates and insights on Zevra Therapeutics stock.
Zevra Therapeutics, Inc. (symbol: ZVRA) is a pioneering rare disease company dedicated to developing transformational therapies for conditions with limited or no treatment options. By combining science, data, and patient needs, Zevra aims to deliver life-changing solutions to individuals living with rare diseases. Their mission is to address these unmet medical needs through unique, data-driven development and commercialization strategies.
Zevra Therapeutics utilizes its proprietary Ligand Activated Therapy (LAT) approach to create improved prodrug versions of FDA-approved medications. These prodrugs target high-need areas such as pain management, ADHD, and other central nervous system diseases. Through this innovative technology, Zevra is overcoming complex drug development challenges and making new therapies accessible to the rare disease community.
Recent achievements include significant advancements in their pipeline projects, particularly in pain and ADHD treatment. The company is also known for its strategic partnerships, which enhance its research and development capabilities and accelerate the commercialization of its therapies. Financially, Zevra has a solid foundation, allowing it to focus on its core mission of addressing rare diseases and improving patients' lives.
For up-to-date information, news, and latest developments, Zevra encourages stakeholders to stay connected through their official contact points:
- Nichol Ochsner: +1 (732) 754-2545, nochsner@zevra.com
- Russo Partners: David Schull: +1 (858) 717-2310, david.schull@russopartnersllc.com
- Russo Partners: Ignacio Guerrero-Ros, Ph.D.: +1 (646) 942-5604, ignacio.guerrero-ros@russopartnersllc.com
Zevra Therapeutics (ZVRA) announced its upcoming addition to the Nasdaq Biotechnology Index (NBI) effective December 23, 2024, as part of the annual index reconstitution. The inclusion reflects the company's meeting of eligibility requirements, including minimum market capitalization, average daily trading volume, and biotechnology industry classification.
The NBI tracks the performance of biotechnology and pharmaceutical securities listed on Nasdaq under a modified capitalization-weighted methodology. CEO Neil F. McFarlane highlighted this as a transformational year for Zevra, noting that the index inclusion will raise the company's profile among biotech funds and portfolio managers.
Zevra Therapeutics (ZVRA) announced organizational changes as part of its transformation into a rare disease therapeutics company. The company is consolidating its development and scientific functions under CMO Adrian Quartel, who will oversee clinical development, quality assurance, and regulatory affairs.
Key changes include the departure of Chief Development Officer Christal Mickle and Chief Scientific Officer Sven Guenther in December 2024. The company is eliminating positions in CMC and Clinical Development, discontinuing in-house drug discovery activities, and closing laboratories in Iowa and Virginia. Future early R&D will be outsourced.
These changes align with Zevra's 2025 Strategic Plan focusing on late-stage clinical and commercial opportunities, built on four pillars: Commercial Excellence, Pipeline and Innovation, Talent and Culture, and Corporate Foundation.
Zevra Therapeutics (NASDAQ: ZVRA) has announced its participation in two major investor conferences in December 2024. President and CEO Neil F. McFarlane will present at the Piper Sandler 36th Annual Healthcare Conference on December 4 at 10:30 a.m. ET, and the Oppenheimer Movers in Rare Disease Summit on December 12 at 2:45 p.m. ET.
Management will be available for one-on-one meetings with registered attendees at both events. The Piper Sandler fireside chat will be available via webcast through the company's investor relations website.
Zevra Therapeutics (ZVRA) announces the commercial availability of MIPLYFFA™ (arimoclomol), the first FDA-approved treatment for Niemann-Pick disease type C (NPC). The medication is indicated for use with miglustat to treat neurological manifestations in patients 2 years and older. The company reports early adoption exceeding expectations, with product now available for shipment within their guided 8-12 week post-approval timeframe. AmplifyAssist™, Zevra's comprehensive patient support program, provides insurance coverage education, copay assistance, and therapy management counseling to facilitate patient access.
Zevra Therapeutics reported Q3 2024 financial results, highlighting the FDA approval of MIPLYFFA™ for Niemann-Pick disease type C treatment. The company reported revenue of $3.7 million and a net loss of ($33.2 million). Key developments include receiving a rare pediatric disease Priority Review Voucher and recording 90 prescription enrollment forms for MIPLYFFA, with 30% approved for reimbursement. Cash position stands at $95.5 million, expected to extend runway into 2027. The company completed a public offering raising $64.5 million and is implementing a strategic plan focused on commercial excellence, pipeline innovation, talent, and corporate foundation.
Zevra Therapeutics (NASDAQ: ZVRA) announced the presentation of data validating the swallow domain's significance in the Niemann-Pick Disease Type C Clinical Severity Scale (NPCCSS) at the 53rd Child Neurology Society Annual Meeting. The study, presented by Dr. Elizabeth Berry-Kravis, involved 12 NPC and swallow experts evaluating scoring categories and instructions.
The findings confirmed that NPCCSS swallow response categories can be consistently interpreted, with score changes reflecting actual changes in patient swallow function. The revised scoring algorithm improves linearity by re-ranking dysphagia categories and creating a separate category for tube-feeding. The R4DNPCCSS endpoint, which includes this revised swallow domain along with ambulation, fine motor skills, and speech domains, showed a favorable treatment difference of -1.51 (P=0.0413) for arimoclomol compared to placebo in the Phase 2/3 study.
Zevra Therapeutics (NASDAQ: ZVRA) has announced its participation in the upcoming Guggenheim Securities Healthcare Innovation Conference. The company's President and CEO, Neil F. McFarlane, will engage in a fireside chat on Wednesday, November 13, 2024, at 4 p.m. ET. The event will be held virtually, and management will be available for one-on-one meetings with registered attendees. Interested parties can access the live webcast through the 'Events & Presentations' section on Zevra's investor relations website at investors.zevra.com.
Zevra Therapeutics (ZVRA) announced it will release its third quarter 2024 financial results and provide a corporate update on November 12, 2024, after market close. The company will host a conference call at 4:30 p.m. ET the same day. The update will include progress on the commercial launches of MIPLYFFA™ and OLPRUVA®, along with updates on clinical stage programs. A webcast replay will be available for 90 days on the company's investor relations website.
Zevra Therapeutics (NASDAQ: ZVRA), a rare disease therapeutics company, has announced its participation in a Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit. The event, presented by Maxim Group , is scheduled for Thursday, October 17, 2024, at 2 p.m. ET. Neil F. McFarlane, President and CEO of Zevra, will represent the company at the panel.
The conference will be streamed live on M-Vest, with investors able to register and watch the discussion through the M-Vest page. For those unable to attend live, an archived version of the presentation will be made available in the 'Events & Presentations' section of Zevra's Investor Relations website at investors.zevra.com.
The National Urea Cycle Disorders Foundation (NUCDF) and Zevra Therapeutics (NasdaqGS: ZVRA) have launched the Check Ammonia Campaign in October to improve the diagnosis of urea cycle disorders (UCDs). The campaign aims to highlight the critical importance of prompt and accurate blood ammonia testing, which is essential for detecting elevated ammonia levels (hyperammonemia), a classic sign of UCDs.
The campaign website, checkammonia.com, offers resources on recognizing and testing for hyperammonemia. Quick diagnosis is important as toxic ammonia levels can rise rapidly in affected individuals, potentially leading to coma and death if left untreated. Newborns with severe UCDs typically become critically ill within 36-48 hours after birth, and it's estimated that up to 20% of sudden infant death syndrome (SIDS) cases may be due to undiagnosed inborn errors of metabolism like UCDs.
FAQ
What is the current stock price of Zevra Therapeutics (ZVRA)?
What is the market cap of Zevra Therapeutics (ZVRA)?
What does Zevra Therapeutics, Inc. specialize in?
What is the company's mission?
What is the Ligand Activated Therapy (LAT) approach?
Which areas of medical needs does Zevra's technology target?
Who are the primary contacts for investor relations?
How does Zevra ensure the financial stability of their projects?
What recent achievements has Zevra made?
What kind of partnerships does Zevra engage in?
How can stakeholders stay updated with Zevra's latest news?
What is the significance of Zevra’s prodrug development?
